Kornimate/medical-research-clean huggingface dataset:
the biofeedback therapy in solitery rectal ulser patients biofeedback therapy

Conditions: Rectal Ulcer

Summary: dissynergic defecation causes solitery rectal ulcer. the biofeedback therapy improves dissynegy and heals soliter rectal ulcer.

dyssynergia treating ulcers caused by treatment with biofeedback

Eligibility criteria:
inclusion criteria: * solitary rectal ulcer in rectosigmoidoscopy * type 1 or 3 dissynergic defecation * to accept to participate to study and sign informed consent exclusion criteria: * previously applied biofeedback * serious psychiatric disorder * previous anorectal surgery * the presence of active malignancy

Keywords: solitery rectal ulcer biofeedback dissynergy
functional and morphological results of rhegmatogenous retinal detachment treated with vitrectomy

Conditions: Retinal Detachment; Vitrectomy

Summary: to examine morphological and functional results after pars plana vitrectomy (ppv) with sf6 gas tamponade due to macula-on and macula-off rhegmatogenous retinal detachment (rrd) during six months of the follow-up.

background: to examine morphological and functional results after pars plana vitrectomy (ppv) with sf6 gas tamponade due to macula-on and macula-off rhegmatogenous retinal detachment (rrd) during six months of the follow-up. methods: the study included 62 eyes that underwent successful ppv with sf6 tamponade with macula-on (34 eyes) and macula-off (28 eyes) rrd preoperatively. the best-corrected visual acuity (bcva), amsler test, m-charts, optical coherence tomography (oct) and microperimetry were performed at 1, 3 and 6 months postoperatively.

Eligibility criteria:
inclusion criteria: * the diagnosed macula-on and macula-off rhegmatogenous retinal detachment. exclusion criteria: * history of uveitis, * diabetic retinopathy, * previous vitreoretinal surgery, * glaucoma or eye trauma, * retinal detachment combined with macular hole or proliferative vitreoretinopathy

Keywords: rhegmatogenous retinal detachment vitrectomy metamorphopsia m-charts microperimetry
examining the role of vitamin d in asthma and chronic obstructive pulmonary disease (copd)

Conditions: Asthma; Pulmonary Disease; Chronic Obstructive

Summary: asthma and chronic obstructive pulmonary disease (copd) are diseases that affect a person's ability to breathe normally. people who do not receive enough vitamin d may have a higher risk of developing asthma or copd. this study will examine previously collected blood samples of participants in three studies to determine whether people with low vitamin d levels have an increased risk of severe asthma or copd.

asthma and copd are among the leading causes of illness in children and adults, respectively. asthma is the most common long-term disease among children in the developed world, and approximately 16 million people in the united states have copd, which is now the fourth most common cause of death in this country. vitamin d, both a nutrient and a hormone, can be taken in through diet and exposure to sunlight. many children and adults have a vitamin d deficiency and there is concern that current recommended intake levels may be inadequate. a vitamin d deficiency can cause immune system dysfunction and may increase the risk of developing immune-mediated disorders, such as multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, and various cancers. because of its role in immune development and function, a vitamin d deficiency may also be related to the development of severe asthma in children and to greater lung function decline in adults, leading to copd. preliminary research shows that people with asthma who take vitamin d have an enhanced response to corticosteroids, a common medication used to treat asthma. this finding suggests that vitamin d could possibly be used to improve asthma treatment. the purpose of this study is to measure vitamin d levels in participants of three previous studies and determine whether lower vitamin d levels are related to the development of severe asthma or copd. this study will examine previously collected blood samples from participants in three studies. there will be no study visits specifically for this study. the three studies include the following: * childhood asthma management program, which is a study that examined the use of inhaled corticosteroids, nedocromil, and placebo in children with mild-to-moderate asthma * genetic epidemiology of asthma in costa rica, which is an ongoing study that is identifying genetic predictors of asthma in costa rican families with asthma * normative aging study, which is a study of aging that is being conducted in men living in boston

Eligibility criteria:
inclusion criteria: * participated in the childhood asthma management program, the genetic epidemiology of asthma in costa rica study, or the normative aging study

Keywords: lung function decline lung function allergy copd vitamin d
essential voice tremor: a study of botulinum toxin treatment and injection augmentation

Conditions: Essential Tremor

Summary: botulinum toxin is the common treatment of choice for patients with essential voice tremor (evt), but results are not universally beneficial to all patients. inconsistent results are noted in the literature and are consistent with the pi's clinical experience. injection augmentation, a well-established treatment for glottic insufficiency, which is a prominent factor in the clinical presentation of essential voice tremor (evt), has not been studied. by treating patients at separate times with botulinum toxin and injection augmentation in an unblinded prospective crossover treatment study, we can assess functional outcomes of these two treatments with the population of patients with essential voice tremor (evt).

the purpose of this study is to compare treatment with botulinum toxin to treatment with injection augmentation in patients diagnosed with essential voice tremor. botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. this is identical to the injections you may have received in the past for your disorder. injection augmentation is the injection of a filler material into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. the flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. it is the routine diagnostic evaluation technique of voice disorders. periodic injections with botulinum toxin (botox) is the current standard of care for patients diagnosed with essential voice tremor, but studies show only about 60% of patients benefit substantially enough to continue treatment. poor vocal fold closure, a common characteristic of essential voice tremor, is treated in other situations (such as vocal fold paralysis or paresis) with injection augmentation; thus there is reason to think that it may be helpful to patients with essential voice tremor, perhaps even to a greater extent than botulinum toxin.

Eligibility criteria:
inclusion criteria: * male and female patients ages 18-100 who have been diagnosed with essential tremor of the voice (evt) diagnosis code 478.75 laryngeal spasm. exclusion criteria: * wcmc subjects under age 18 * pregnant patients * patients with laryngeal pathology besides tremor, including but not limited to polyps and other benign lesions, precancerous or cancerous changes, vocal fold paralysis, or other laryngeal disorders of mobility

Keywords: botulinum toxin injection augmentation essential voice tremor
neurobiology of opioid dependence: 4 - 4

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to determine the effect of chronic naltrexone pre-treatment on the response to yohimbine in healthy volunteers.


Eligibility criteria:
please contact site for information.

Keywords: opioid disorders
the effects of tele-rehabilitation interventions in parkinson's patients

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is the most common neurodegenerative movement disorder. the main motor symptoms of pd are tremor, rigidity, bradykinesia, and postural instability. current treatments of the disease provide control of motor symptoms but do not change its development. parkinson's patients should receive regular rehabilitation as part of their treatment. telerehabilitation (tr) practices and studies examining the effectiveness of these practices are needed in order to reduce the impact of the current pandemic period and environmental and personal causes in accessing rehabilitation services. in this thesis, in order to examine the effects of two different tr methods on physical parameters and activities of daily living in parkinson's patients, parkinson's patients who are eligible the inclusion criteria will be randomized according to the row of application and divided into 2 groups. evaluations to determine the functionality, activities of daily living, falling activity, quality of life and fatigue level will be applied both groups. one group will be applied video exercise program prepared individually via tr system, and the other group will receive an exercise brochure via the tr system and patients will be asked to do the exercises 3 days a week for 8 weeks. then the initial evaluations will be repeated. it is aimed to increase functional capacity, independence in daily living activities and quality of life, and reduce the number of falls and fatigue levels with exercise training to be applied to people with parkinson's. investigators think that present study not only will contribute to the field of tr applications in pd, but also will provide access to rehabilitation services and help control symptoms of parkinson's patients who cannot go to hospital, rehabilitation centers and cannot access rehabilitation services at home. hypotheses: h0-tr applications have no effect on the level of independence in physical parameters and activities of daily living in individuals with pd. h1-tr applications have positive effects on physical parameters and independence in activities of daily living in individuals with pd.


Eligibility criteria:
inclusion criteria: * having been diagnosed with parkinson's disease at least 1 year ago by a neurologist * hoehn and yahr score ≤3 * have an internet infrastructure where the system can be accessed at home * not participating in a standardized physiotherapy program in the last 3 months exclusion criteria: * presence of blurred or low vision problems * hearing and speech impairment affecting participation in the system * epilepsy * presence of pregnancy * having any cognitive problems that prevent using the system

Keywords: telerehabilitation physical therapy modalities nervous system diseases home-based physiotherapy
hip fracture in individuals under 60 years of age

Conditions: Hip Fractures

Summary: this study prospectively analyses and describes a cohort of non-elderly hip fracture patients at four orthopaedic departments in two scandinavian countries regarding epidemiology, treatment, patient reported outcome measures, functional outcome as well as clinical results.

hip fracture is common and well studied in the elderly population, but quite rare in the non-elderly and scarcely investigated in the literature. this prospective observational study focuses on individuals between 18 and 59 years old who have incurred a hip fracture and been treated at any of the participating orthopaedic departments in sweden or denmark. the study group is analysed and described at the time of the fracture and are followed during two years. the patients' treatment follows the departments' standard rationale, there is no intervention in the study. patients are included, after being informed and consent to participate is given, at the ward when they are admitted at the time of the fracture. the study comprises written enquiries (patient reported outcome measures, prom) regarding hip- and global health before the fracture as well as interview and medical files and x-ray information regarding previous illness and use of medication, information about the injury, fracture type and treatment. blood samples are used to investigate possible comorbidities and evaluate the hormonal and nutritional status and dual energy x-ray absorptiometry (dxa) is analysed with regards to reduced bone mineral density (osteopenia/-porosis). for patients with a femoral neck fracture who are treated with osteosynthesis, mri with metal reduction is performed post-operatively and at 4 and 12 months to assess fracture healing and avascular necrosis of the femoral head. patients are followed up at 6 weeks by written prom-enquiries by mail, and at 4, 12 and 24 months post-operatively with x-ray and visits in the outpatient clinic.

Eligibility criteria:
inclusion criteria: * acute non-pathologic hip fracture regardless of trauma energy level or previous medical conditions. exclusion criteria: * fracture older than four weeks. * not able to follow up, e.g. not living in the department area.

Keywords: hip fractures adult middle-aged dxa-scan osteoporosis
hepatocellular carcinoma growth and molecular aggressiveness

Conditions: Cirrhosis; Hepatocellular Carcinoma

Summary: our long-term objective is to develop a new tool based on a (molecular-biology) integrated imaging technology able to characterize and categorize hepatocellular carcinoma (hcc) patients in need of liver transplant (lt). to this end, our study aims at correlating specific imaging traits and fractional growth of individual tumors collected over a restricted time frame (t0 and at week 7 after first tumor detection), with a "molecular signature", obtained by custom microarray, histochemical and cytokine analysis. this should allow us to translate a series of purely morphologic information into a meaningful pathobiologic data sets. validation of the integrated molecular-imaging tool will be performed prospectively by correlating the imaging-molecular data with hcc outcome in term of survival and disease-free survival after down staging procedures.

organ allocation in our region is regulated according to meld score. patients with hepatocellular carcinoma (hcc) receive an additional score depending on size of the tumor and the time spent in transplant waiting list. however, the advantage given to these patients is uniform and does not take into account the profound biological heterogeneity of individual hccs. to make the additional score righteous, the investigators need to identify patients with aggressively growing hcc who require salvage transplantation while those with slow-growing hcc do not deserve the additional score. all cirrhotics with suspect hcc identified at routine us screening will be therefore enrolled in the prospective imaging and bio-molecular study. they will be subjected to two computed tomography (ct) exams at 7 weeks interval to define fractional tumor growth and imaging traits, baseline us-guided liver biopsy for microarray and histochemical characterization, serum sampling for cytokine assay. survival, disease-free survival after downstaging and transplant outcome will be recorded and analyzed in relation with imaging and molecular data. the investigators expect to set up an accurate imaging and molecular diagnostic tool able to identify patients with aggressive hcc requiring urgent access to transplant, reliable in predicting survival, standardisable and not too expensive.

Eligibility criteria:
inclusion criteria: * cirrhotic patients at first us identification of a focal lesion compatible with hcc * age \> than 18 years * no contraindications to performance of ct * no contraindications to performance of us-guided liver biopsy exclusion criteria: patients will be excluded if * are unable to give informed consent to the study; * liver tissue obtained at biopsy is insufficient to perform molecular/histochemical study

Keywords: hcc computed tomography gene expression fractional growth
randomised, double-blind study to investigate the safety and efficacy of brotizolam in insomnia outpatients.

Conditions: Sleep Initiation and Maintenance Disorders

Summary: to investigate the efficacy and safety of brotizolam in the treatment of patients with insomnia in comparison with that of estazolam

it is intended to recruit 240 insomnia outpatients in this study, 120 patients receiving brotizolam + estazolam placebo (test group) and 120 patients given estazolam + brotizolam placebo (control group). study hypothesis: brotizolam can be safely used in insomnia patients in china. and brotizolam 0.25mg is non-inferior with estazolam 1-2mg in treatment of insomnia patients in china comparison(s): estazolam 1-2mg

Eligibility criteria:
inclusion_criteria: patients will be eligible for enrollment of this study if they meet all of the following criteria: * willing and able to provide written informed consent * male or female, aged 18 - 65 (including 18 and 65) * diagnosed as insomnia by the criteria of ccmd-3: exclusion_criteria: * who received any central nervous system drugs within one week before visit 2(baseline) * continuous use of hypnotic agents for more than 3 months recently * history of inefficiency with benzodiazepine-type hypnotics * who have a history of obvious hypersensitivity * hamilton depression rating scale (hamd)18 * who was diagnosed with other mental illness * with serious diseases of heart, liver and kidney, etc * who had sleep apnoea syndrome * who had epileptic seizures within one year * with angle closure glaucoma that is acute or easy to occurred * whose ast or alt values are 2 times of normal upper limit * whose cr or bun values are 2 times of normal upper limit * who are known to be prone to the abuse of alcohol (i.e. history of evidence of acute or chronic abuse), or any other addictive agents * who is participating in other clinical trial, or have participated in a clinical study of any other drug in one month prior to visit 2 (baseline). in addition, patients who has been randomized in this trial and then withdrew can not be enrolled again. * all pregnant, lactational women and women who have the plan of pregnancy. * who are unwilling to or not able to complete the whole clinical trial * other patients who are unsuitable to be included in the trial judged by investigator
propranolol for diabetic retinopathy

Conditions: Proliferative Diabetic Retinopathy

Summary: this study is investigating if the oral beta antagonist propranolol can induce regression of retinal neovascularization associated with proliferative diabetic retinopathy.

oral propranolol 120mg daily will be given to 10 patients with proliferative diabetic retinopathy over a 12 week period to evaluate the effect on retinal neovascularization.

Eligibility criteria:
inclusion criteria: * age \>=18 years * eyes with proliferative diabetic retinopathy and neovascularization * eyes with a history of panretinal photocoagulation treatment and persistent neovascularization deemed by the investigator to be a potential threat to visual acuity either by causing a vitreous hemorrhage or tractional retinal detachment. (group 1 - maximum 5 eyes enrolled with these characteristics) * eyes without a history of panretinal photocoagulation treatment, but that do not have high-risk proliferative diabetic retinopathy characteristics (i.e. these are eyes that have early proliferative diabetic retinopathy that are not yet at a high-risk for vitreous hemorrhage and tractional retinal detachment such that panretinal photocoagulation laser may be deferred). (group 2 - maximum 5 eyes enrolled with these characteristics) exclusion criteria: * either panretinal photocoagulation laser or focal/grid laser into study eye within 3 months of study enrollment * anti-vascular endothelial growth factor injection into study eye within 3 months of study enrollment * contraindications to beta-blockers such as: allergy, previous intolerance, abnormally slow heart rates, asthma or chronic obstructive pulmonary disease, use of medications that have an effect on certain drug metabolic pathways that may cause interactions. * known coronary arterial disease or left ventricular dysfunction, or known peripheral vascular disease * resting heart rate \<60 or systolic blood pressure \<90 and/or diastolic blood pressure \<50 * pregnancy * all patients will either be post-menopausal, have adequate birth control and, if of childbearing age, will have a urinary pregnancy test performed * allergy to fluorescein dye * media opacity obscuring adequate determination of neovascularization including dense cataract or dense vitreous hemorrhage * patient is already taking an oral beta-blocker * vulnerable populations such as prisoners and minors will also be excluded

Keywords: beta-antagonist propranolol diabetic retinopathy diabetes angiogenesis neovascularization
effect of turmeric on pruritus in hemodialysis patients

Conditions: End Stage Renal Failure

Summary: the purpose of this study is to see whether turmeric can be effective in treatment of pruritus in hemodialysis patients.

pruritus is a common in hemodialysis patients and many treatment recommended for it . as turmeric has anti-inflammatory , anti-cytokine and anti-oxidant effect it may effective in treatment of uremic pruritus. thus we compared turmeric with placebo in this study

Eligibility criteria:
inclusion criteria: * hemodialysis for more than 3 months * more than 18 years old * pruritus exclusion criteria: * use other treatment for pruritus

Keywords: hemodialysis turmeric pruritus
prevalence and incidence of central airway obstruction in advanced lung cancer

Conditions: Lung Cancer

Summary: lung cancer may cause central airway obstruction through several different mechanisms (invasion by the primary tumor, invasion by metastatic lymph nodes, airway metastasis). the aim of the present study is to determine the prevalence at the time of diagnosis, the incidence at 1 year from the diagnosis, and the predictors of central airway obstruction associated with advanced lung cancer.


Eligibility criteria:
inclusion criteria: * advanced lung cancer with indication for chemotherapy or chemotherapy + radiation therapy exclusion criteria: * age \< 18 year * pregnancy * refusal to sign informed consent
laser therapy for perioral dermatitis

Conditions: Perioral Dermatitis

Summary: perioral dermatitis is an inflammation of the skin around the mouth. the cause of perioral dermatitis is unknown. current treatment methods include oral antibiotics and topical calcenurin inhibitors, both of which produce side effects and have been relatively ineffective in the treatment of perioral dermatitis. the investigators hope to assess the efficacy of laser therapy in treatment of perioral dermatitis by using laser therapy on one half of the patients face and having patients apply topical medication (clindamycin) to their face for 8 weeks. the side of their face that receives laser therapy will be randomized. the investigators will assess the efficacy of laser therapy by counting the number of lesions that patients have before and after laser therapy, comparing photos of patient's perioral dermatitis before and after treatment, and having patient's rate their satisfaction of the treatment.


Eligibility criteria:
inclusion criteria: * age 18 years or older * perioral dermatitis for greater than 1 month * willing to return for follow-up visits 2 weeks, 4 weeks and 8 weeks following treatment. exclusion criteria: * skin type v or vi (due to risk of hyperpigmentation) * pregnant * breastfeeding * unable to understand english * mentally impaired * incarcerated

Keywords: perioral dermatitis laser therapy